Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
Hosted on MSN10h
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You TradeThe most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $38.36, reflecting a -1.26% shift from the previouse trading day's closing. The stock trailed the S&P 500, which ...
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...
Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...
The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...
Professor Kevin J. Zwezdaryk and Chandler H. Monk discuss CRISPR and diagnostics, focusing on the development of a portable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback